

Shu-Hsia Chen, PhD  
Dr. Mary and Ron Neal Cancer Center  
Academic Institute  
Research Institute  
Department of Medicine  
Houston Methodist  
Weill Cornell Medical College



**Type of address: Postal address.**  
6445 Main St., P21-34  
Houston  
Texas  
United States  
**Type of address: Postal address.**  
6670 Bertner Ave  
Houston  
Texas  
United States  
**Type of address: Postal address.**  
6671 Bertner Ave  
Houston  
Texas  
United States  
**Type of address: Postal address.**  
6550 Fannin St., Suite 1001  
Houston  
Texas  
United States

## Research interests

Over the past years, my laboratory has focused on gene therapies and cancer immunotherapies. My laboratory has also, to a large extent, focused on elucidating the mechanisms underlying the establishment of immune suppressive tumor microenvironments, a major impediment to the success of immune-based cancer therapies and overcoming cancer cells' resistance to chemo-radiation therapies. Specifically, we have been examining the mechanisms of immune suppression that are mediated by myeloid derived suppressor cells, macrophages, B cells, and T regulatory cells. In addition, we have been studying the biology of cancer initiating cells, the control of differentiation of myeloid cells and tumor associated macrophages, and modulation of the tumor microenvironment, all of which will influence our ability to control malignant disease.

Our laboratory is working to further define the activation of cancer initiating cells, as well as the immunological changes inside the distinct tumor microenvironment, after administration of radiation therapy, chemotherapy, targeted therapeutics, T cell therapy, and antibody-based novel immune checkpoint therapies. This will help researchers and clinicians integrate conventional therapies with the ideal immunotherapies, thereby achieving the maximal therapeutic efficacy in patients. We are also investigating whether and how targeting therapeutics can overcome the stress-/inflammation-induced immune suppression that subsequently interferes with the success of immunotherapy and chemo/radiation therapy.

One of the primary aims of my lab is to examine how novel immune checkpoint pathways influence tumor growth, receptor/ligand interaction, and the tumor microenvironment. We also aim to develop novel therapeutic agents that effectively target tumors or tumor stromal cells, causing an increase local antigen priming and T cell activation/infiltration for subsequent immunotherapy. This is a key component of achieving long-term tumor remission and lasting immune memory. Using our newly developed immune checkpoints, nanotechnology, and T cell therapy, we can improve tumor targeting and reduce toxicity in patients. Collaborating with colleagues, we have been continually successful in obtaining support from NIH, DOD, and pharmaceutical companies, with the aim of developing novel therapeutic strategies through preclinical and clinical trials.

Program 1. Modulate tumor microenvironment to facilitate cancer immune therapy.

Program 2. Identify novel immune checkpoints, reprogram of myeloid cell/macrophage function and stress signaling to develop novel immune therapy strategies.

Program 3. Tumor inflammation on the regulation of tumor progression and metastases.

Program 4. The MDSC and macrophage mediated immune regulation in human health

Program 5. Synergist effect of innate and adaptive immune response for immune therapy

## Employment

**Emily Herrmann Chair in Immunology Research**  
Dr. Mary and Ron Neal Cancer Center  
United States  
Jul 1 2019 → present

**Professor of Immunology in Medicine**

Academic Institute  
Houston, United States  
Aug 1 2019 → present

**Full Member**

Research Institute  
United States  
Jul 1 2019 → present

**Department of Medicine**

United States  
Jul 1 2019 → present

**Houston Methodist**

Houston, United States  
May 22 2017 → present

**Weill Cornell Medical College**

Jan 1 2020 → present

**Research output****Nanofluidic delivery implant sustains localization and maximizes efficacy of intratumoral immunotherapy**

Liu, H. C., Di Trani, N., Conte, M., Nguyen, D. C., Jokonya, S., Wu, A., Vander Pol, R., Joubert, A. L., Facchi, I., Wood, A. M., Ho, J., Pesaresi, F., Cauda, V., Chen, S. H., Liu, X., Stayton, P. S., Chua, C. Y. X. & Grattoni, A., Jun 2024, In: *Nano Today*. 56, 102258.

**Long Interspersed Nuclear Element-1 Analytes in Extracellular Vesicles as Tools for Molecular Diagnostics of Non-Small Cell Lung Cancer**

Bowers, E. C., Cavalcante, A. M., Nguyen, K., Li, C., Wang, Y., El-Zein, R., Chen, S. H., Kim, M. P., McKay, B. S. & Ramos, K. S., Jan 2024, In: *International journal of molecular sciences*. 25, 2, 1169.

**LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy**

Mai, S., Hodges, A., Chen, H. M., Zhang, J., Wang, Y. L., Liu, Y., Nakatsu, F., Wang, X., Fang, J., Xu, Y., Davidov, V., Kang, K., Pingali, S. R., Ganguly, S., Suzuki, M., Konopleva, M., Prinzing, B., Zu, Y., Gottschalk, S., Lu, Y., & 2 others Chen, S. H. & Pan, P. Y., Dec 15 2023, In: *Cancer research*. 83, 24, p. 4047-4062 16 p.

**Intratumoral nanofluidic system enhanced tumor biodistribution of PD-L1 antibody in triple-negative breast cancer**

Liu, H-C., Capuani, S., Badachhape, A. A., Di Trani, N., Davila Gonzalez, D., Vander Pol, R. S., Viswanath, D. I., Saunders, S., Hernandez, N., Ghaghada, K. B., Chen, S-H., Nance, E., Annapragada, A. V., Chua, C. Y. X. & Grattoni, A., Nov 2023, In: *Bioengineering and Translational Medicine*. 8, 6, p. e10594 e10594.

**Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics**

Louis Sam Titus, A. S. C., Tan, Y., Tran, P., Lindblom, J., Ivbievbiokun, M., Xu, Y., Zheng, J., Parodis, I., Cai, Q., Chang, A., Chen, S-H., Zhao, M. & Mohan, C., Sep 2023, In: *Clinical immunology (Orlando, Fla.)*. 254, p. 109713 109713.

**A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer**

Guan, J., Sun, K., Guerrero, C. A., Zheng, J., Xu, Y., Mathur, S., Teh, B. S., Farach, A., Zhang, J., Butler, E., Pan, P. Y., Zsigmond, E., Mei, Z., Mejia, J., Chen, S. H., Chang, J. C. & Bernicker, E. H., Aug 24 2023, (E-pub ahead of print) In: *International Journal of Radiation Oncology Biology Physics*. 118, 5, p. 1531-1540 10 p.

**Osteoprogenitor-GMP crosstalk underpins solid tumor-induced systemic immunosuppression and persists after tumor removal**

Hao, X., Shen, Y., Chen, N., Zhang, W., Valverde, E., Wu, L., Chan, H. L., Xu, Z., Yu, L., Gao, Y., Bado, I., Michie, L. N., Rivas, C. H., Dominguez, L. B., Aguirre, S., Pingel, B. C., Wu, Y. H., Liu, F., Ding, Y., Edwards, D. G., & 10 othersLiu, J., Alexander, A., Ueno, N. T., Hsueh, P. R., Tu, C. Y., Liu, L. C., Chen, S. H., Hung, M. C., Lim, B. & Zhang, X. H. F., May 4 2023, In: *Cell Stem Cell.* 30, 5, p. 648-664.e8

**Multi-omics-based analysis of high grade serous ovarian cancer subtypes reveals distinct molecular processes linked to patient prognosis**

Wang, Y. A., Neff, R., Song, W. M., Zhou, X., Vatansever, S., Walsh, M. J., Chen, S. H. & Zhang, B., Apr 2023, In: *FEBS Open Bio.* 13, 4, p. 617-637 21 p.

**Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer**

Liu, H. C., Davila Gonzalez, D., Viswanath, D. I., Vander Pol, R. S., Saunders, S. Z., Di Trani, N., Xu, Y., Zheng, J., Chen, S. H., Chua, C. Y. X. & Grattoni, A., Mar 24 2023, In: *Advanced Science.* 10, 9, p. e2206873 2206873.

**Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention**

Zhang, Q., Pan, J., Xiong, D., Zheng, J., McPherson, K. N., Lee, S., Huang, M., Xu, Y., Chen, S-H., Wang, Y., Hildebrandt Ruiz, L. & You, M., 2023, In: *Frontiers in immunology.* 14, p. 1166951 1166951.

**A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer**

Sun, K., Xu, Y., Zhang, L., Niravath, P., Darcourt, J., Patel, T., Teh, B. S., Farach, A. M., Guerrero, C., Mathur, S., Sulzenfuss, M. A., Gupta, N., Schwartz, M. R., Haley, S. L., Nair, S., Li, X., Nguyen, T. T. A., Butner, J. D., Ensor, J., Mejia, J. A., & 5 othersMei, Z., Butler, E. B., Chen, S. H., Bernicker, E. H. & Chang, J. C., Oct 14 2022, In: *Clinical cancer research : an official journal of the American Association for Cancer Research.* 28, 20, p. 4392-4401 10 p.

**A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: The RAD VACCINE MIBC trial**

Satkunasivam, R., Lim, K., Teh, B. S., Guzman, J., Zhang, J., Farach, A., Chen, S. H., Wallis, C. J. D., Efsthathiou, E., Esnaola, N. F. & Sonpavde, G. P., Aug 2022, In: *Future Oncology.* 18, 25, p. 2771-2781 11 p.

**Chemotherapy Coupled to Macrophage Inhibition Induces T-cell and B-cell Infiltration and Durable Regression in Triple-Negative Breast Cancer**

Singh, S., Lee, N., Pedroza, D. A., Bado, I. L., Hamor, C., Zhang, L., Aguirre, S., Hu, J., Shen, Y., Xu, Y., Gao, Y., Zhao, N., Chen, S. H., Wan, Y. W., Liu, Z., Chang, J. T., Hollern, D., Perou, C. M., Zhang, X. H. F. & Rosen, J. M., Jun 15 2022, In: *Cancer research.* 82, 12, p. 2281-2297 17 p.

**Antibody-Mediated LILRB2-Receptor Antagonism Induces Human Myeloid-Derived Suppressor Cells to Kill *Mycobacterium tuberculosis***

Singh, V. K., Khan, A., Xu, Y., Mai, S., Zhang, L., Mishra, A., Restrepo, B. I., Pan, P. Y., Chen, S. H. & Jagannath, C., Jun 10 2022, In: *Frontiers in immunology.* 13, p. 865503 865503.

**Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma *in situ* progression: insights from a multiscale modeling study**

Butner, J. D., Dogra, P., Chung, C., Ruiz-Ramírez, J., Nizzero, S., Plodinec, M., Li, X., Pan, P. Y., Chen, S. H., Cristini, V., Ozpolat, B., Calin, G. A. & Wang, Z., May 2022, In: *Cell death & disease.* 13, 5, 485.

**Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome**

Jewell, B. E., Xu, A., Zhu, D., Huang, M. F., Lu, L., Liu, M., Underwood, E. L., Park, J. H., Fan, H., Gingold, J. A., Zhou, R., Tu, J., Huo, Z., Liu, Y., Jin, W., Chen, Y. H., Xu, Y., Chen, S. H., Rainusso, N., Berg, N. K., & 9 othersBazer, D. A., Vellano, C., Jones, P., Eltzschig, H. K., Zhao, Z., Kaipparettu, B. A., Zhao, R., Wang, L. L. & Lee, D. F., Dec 29 2021, In: *PLoS Genetics.* 17, 12, e1009971.

**A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer**

Chung, A. W., Anand, K., Anselme, A. C., Chan, A. A., Gupta, N., Venta, L. A., Schwartz, M. R., Qian, W., Xu, Y., Zhang, L., Kuhn, J., Patel, T., Rodriguez, A. A., Belcheva, A., Darcourt, J., Ensor, J., Bernicker, E., Pan, P. Y., Chen, S. H., Lee, D. J., & 2 othersNiravath, P. A. & Chang, J. C., Dec 15 2021, In: *Science translational medicine*. 13, 624, abj5070.

**The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells**

Hinkle, L., Liu, Y., Meng, C., Chen, Z., Mai, J., Zhang, L., Xu, Y., Pan, P. Y., Chen, S. H. & Shen, H., Dec 15 2021, In: *Journal of Immunology*. 207, 12, p. 3131-3140 10 p.

**Nutrient supplements from selected botanicals mediated immune modulation of the tumor microenvironment and antitumor mechanism**

Chen, H. M., Sun, L., Pan, P. Y., Wang, L. H. & Chen, S. H., Dec 2021, In: *Cancer Immunology, Immunotherapy*. 70, 12, p. 3435-3449 15 p.

**A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells**

Welte, T., Mai, J., Zhang, Z., Tian, S., Zhang, G., Xu, Y., Zhang, L., Chen, S. S., Wang, T. & Shen, H., Nov 19 2021, In: *iScience*. 24, 11, p. 103349 103349.

**The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells**

Hinkle, L., Liu, Y., Meng, C., Chen, Z., Mai, J., Zhang, L., Xu, Y., Pan, P-Y., Chen, S-H. & Shen, H., Nov 12 2021, (E-pub ahead of print) In: *Journal of immunology* (Baltimore, Md. : 1950).

**Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling**

Butner, J. D., Martin, G. V., Wang, Z., Corradetti, B., Ferrari, M., Esnaola, N., Chung, C., Hong, D. S., Welsh, J. W., Hasegawa, N., Mittendorf, E. A., Curley, S. A., Chen, S. H., Pan, P. Y., Libutti, S. K., Ganesan, S., Sidman, R. L., Pasqualini, R., Arap, W., Koay, E. J., & 1 othersCristini, V., Nov 9 2021, In: *eLife*. 10, e70130.

**Virus-Mimic mRNA Vaccine for Cancer Treatment**

Meng, C., Chen, Z., Mai, J., Shi, Q., Tian, S., Hinkle, L., Li, J., Zhang, Z., Ramirez, M., Zhang, L., Xu, Y., Zhang, J., Pan, P. Y., Chen, S. H., Li, H. & Shen, H., Nov 2021, In: *advanced therapeutics*. 4, 11, 2100144.

**Amphibian regeneration and mammalian cancer: Similarities and contrasts from an evolutionary biology perspective: Comparing the regenerative potential of mammalian embryos and urodeles to develop effective strategies against human cancer**

Corradetti, B., Dogra, P., Pisano, S., Wang, Z., Ferrari, M., Chen, S-H., Sidman, R. L., Pasqualini, R., Arap, W. & Cristini, V., Jul 2021, In: *BioEssays*. 43, 7, p. e2000339 2000339.

**Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1**

Liu, H. C., Viswanath, D. I., Pesaresi, F., Xu, Y., Zhang, L., Di Trani, N., Paez-Mayorga, J., Hernandez, N., Wang, Y., Erm, D. R., Ho, J., Susnjar, A., Liu, X., Demaria, S., Chen, S. H., Teh, B. S., Butler, E. B., Xuan Chua, C. Y. & Grattoni, A., Jun 1 2021, In: *International Journal of Radiation Oncology Biology Physics*. 110, 2, p. 492-506 15 p.

**Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection**

Liu, X., Wang, Y. L., Wu, J., Qi, J., Zeng, Z., Wan, Q., Chen, Z., Manandhar, P., Cavener, V. S., Boyle, N. R., Fu, X., Salazar, E., Kuchipudi, S. V., Kapur, V., Zhang, X., Umetani, M., Sen, M., Willson, R. C., Chen, S. H. & Zu, Y., Apr 26 2021, In: *Angewandte Chemie - International Edition*. 60, 18, p. 10273-10278 6 p.

**Myeloid-derived suppressor cells as cellular immunotherapy in transplantation and autoimmune diseases**

Zhang, J., Hodges, A., Chen, S. H. & Pan, P. Y., Apr 2021, In: *Cellular Immunology*. 362, 104300.

**Corrigendum: Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment**

Davidov, V., Jensen, G., Mai, S., Chen, S. H. & Pan, P. Y., Feb 1 2021, In: *Frontiers in immunology*. 11, p. 645213 645213.

**Analyzing One Cell at a TIME: Analysis of Myeloid Cell Contributions in the Tumor Immune Microenvironment**  
Davidov, V., Jensen, G., Mai, S., Chen, S. H. & Pan, P. Y., Sep 2 2020, In: *Frontiers in immunology*. 11, 1842.

**Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy**  
Butner, J. D., Elgarnainy, D., Wang, C. X., Wang, Z., Chen, S. H., Esnaola, N. F., Pasqualini, R., Arap, W., Hong, D. S., Welsh, J., Koay, E. J. & Cristini, V., May 2020, In: *Science Advances*. 6, 18, p. eaay6298 eaay6298.

**The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells**  
Zhang, J., Chen, H. M., Ma, G., Zhou, Z., Raulet, D., Rivera, A. L., Chen, S. H. & Pan, P. Y., Aug 1 2019, In: *Leukemia*. 33, 8, p. 2078-2089 12 p.

**Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity**  
Chen, H-M., van der Touw, W., Wang, Y. S., Kang, K., Mai, S., Zhang, J., Alsina-Beauchamp, D., Duty, J. A., Mungamuri, S. K., Zhang, B., Moran, T., Flavell, R., Aaronson, S., Hu, H-M., Arase, H., Ramanathan, S., Flores, R., Pan, P-Y. & Chen, S-H., Dec 3 2018, In: *The Journal of clinical investigation*. 128, 12, p. 5647-5662 16 p.

**Glatiramer acetate enhances myeloid-derived suppressor cell function via recognition of paired Ig-like receptor B**  
Van Der Touw, W., Kang, K., Luan, Y., Ma, G., Mai, S., Qin, L., Bian, G., Zhang, R., Mungamuri, S. K., Hu, H. M., Zhang, C. C., Aaronson, S. A., Feldmann, M., Yang, W. C., Chen, S. H. & Pan, P. Y., Sep 15 2018, In: *Journal of Immunology*. 201, 6, p. 1727-1734 8 p.

**Leukocyte immunoglobulin-like receptors in human diseases: An overview of their distribution, function, and potential application for immunotherapies**  
Zhang, J., Mai, S., Chen, H-M., Kang, K., Li, X. C., Chen, S. H. & Pan, P. Y., Aug 1 2017, In: *Journal of Leukocyte Biology*. 102, 2, p. 351-360 10 p.

**LILRB receptor-mediated regulation of myeloid cell maturation and function**  
van der Touw, W., Chen, H. M., Pan, P. Y. & Chen, S. H., Aug 1 2017, In: *Cancer Immunology, Immunotherapy*. 66, 8, p. 1079-1087 9 p.

**Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards**  
Bronte, V., Brandau, S., Chen, S. H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., Rodriguez, P. C., Sica, A., Umansky, V., Vonderheide, R. H. & Gabrilovich, D. I., Jul 6 2016, In: *Nature Communications*. 7, 12150.

**5-Fluorouracil targets thymidylate synthase in the selective suppression of  $T_H17$  cell differentiation**  
Wang, J., Peng, L., Zhang, R., Zheng, Z., Chen, C., Cheung, K. L., Cui, M., Bian, G., Xu, F., Chiang, D., Hu, Y., Chen, Y., Lu, G., Yang, J., Zhang, H., Yang, J., Zhu, H., Chen, S. H., Liu, K., Zhou, M. M., & 4 others Sikora, A. G., Li, L., Jiang, B. & Xiong, H., Apr 12 2016, In: *Oncotarget*. 7, 15, p. 19312-19326 15 p.

**Myeloid-derived suppressor cells as an immune parameter in patients with concurrent sunitinib and stereotactic body radiotherapy**  
Chen, H. M., Ma, G., Gildener-Leapman, N., Eisenstein, S., Coakley, B. A., Ozao, J., Mandeli, J., Divino, C., Schwartz, M., Sung, M., Ferris, R., Kao, J., Wang, L. H., Pan, P. Y., Ko, E. C. & Chen, S. H., Sep 15 2015, In: *Clinical Cancer Research*. 21, 18, p. 4073-4085 13 p.

**DC-SIGN<sup>+</sup> Macrophages Control the Induction of Transplantation Tolerance**  
Conde, P., Rodriguez, M., van der Touw, W., Jimenez, A., Burns, M., Miller, J., Brahmachary, M., Chen, H. M., Boros, P., Rausell-Palamos, F., Yun, T. J., Riquelme, P., Rastrojo, A., Aguado, B., Stein-Streilein, J., Tanaka, M., Zhou, L., Zhang, J., Lowary, T. L., Ginhoux, F. & 12 others Park, C. G., Cheong, C., Brody, J., Turley, S. J., Lira, S. A., Bronte, V., Gordon, S., Heeger, P. S., Merad, M., Hutchinson, J., Chen, S. H. & Ochando, J., Jun 16 2015, In: *Immunity*. 42, 6, p. 1143-1158 16 p.

**Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice**

Wang, Y., Chen, K., Wu, Z., Liu, Y., Liu, S., Zou, Z., Chen, S. H. & Qu, C., Dec 1 2014, In: International Journal of Infectious Diseases. 29, p. 31-36 6 p.

**Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: Final report of a prospective clinical trial**

Kao, J., Chen, C. T., Tong, C. C. L., Packer, S. H., Schwartz, M., Chen, S. H. & Sung, M. W., Jun 2014, In: Targeted Oncology. 9, 2, p. 145-153 9 p.

**Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy**

Eisenstein, S., Coakley, B. A., Briley-Saebo, K., Ma, G., Chen, H. M., Meseck, M., Ward, S., Divino, C., Woo, S., Chen, S. H. & Pan, P. Y., Aug 15 2013, In: Cancer research. 73, 16, p. 5003-5015 13 p.

**T cell-derived inducible nitric oxide synthase switches off the Th17 cell differentiation**

Yang, J., Zhang, R., Lu, G., Shen, Y., Peng, L., Zhu, C., Cui, M., Wang, W., Arnaboldi, P., Tang, M., Gupta, M., Qi, C. F., Jayaraman, P., Zhu, H., Jiang, B., Chen, S. H., He, J. C., Ting, A. T., Zhou, M. M., Kuchroo, V. K., & 4 others Morse, H. C., Ozato, K., Sikora, A. G. & Xiong, H., Jul 2013, In: Journal of Experimental Medicine. 210, 7, p. 1447-1462 16 p.

**Polarization and reprogramming of myeloid-derived suppressor cells**

Yang, W. C., Ma, G., Chen, S. H. & Pan, P. Y., Jun 2013, In: Journal of molecular cell biology. 5, 3, p. 207-209 3 p.

**Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice**

Martel, C., Li, W., Fulp, B., Platt, A. M., Gautier, E. L., Westerterp, M., Bittman, R., Tall, A. R., Chen, S. H., Thomas, M. J., Kreisel, D., Swartz, M. A., Sorci-Thomas, M. G. & Randolph, G. J., Apr 1 2013, In: Journal of Clinical Investigation. 123, 4, p. 1571-1579 9 p.

**Programming of MDSC: New opportunities for targeted therapy**

Svider, P., Chen, S. H., Sikora, A. G. & Yang, W. C., Jan 1 2013, *The Tumor Immunoenvironment*. Springer Netherlands, p. 567-584 18 p.

**Myeloid-derived suppressor cells as a trojan horse: A cellular vehicle for the delivery of oncolytic viruses**

Pan, P. Y., Chen, H. M. & Chen, S. H., 2013, In: Oncoimmunology. 2, 8, e25083.

**Myeloid-derived suppressor cells in transplantation and cancer**

Ochando, J. C. & Chen, S. H., Dec 2012, In: Immunologic Research. 54, 1-3, p. 275-285 11 p.

**Erratum: Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development (Nature (2012) 485 (656-660) DOI: 10.1038/nature11095)**

Zheng, J., UmiKawa, M., Cui, C., Li, J., Chen, X., Zhang, C., Huynh, H., Kang, X., Silvany, R., Wan, X., Ye, J., Cant, A. P., Chen, S. H., Wang, H. Y., Sally Ward, E. & Zhang, C. C., Aug 30 2012, In: Nature. 488, 7413, p. 684 1 p.

**$\Gamma$ -H2AX kinetics as a novel approach to high content screening for small molecule radiosensitizers**

Fu, S., Yang, Y., Tirtha, D., Yen, Y., Zhou, B. S., Zhou, M. M., Ohlmeyer, M., Ko, E. C., Cagan, R., Rosenstein, B. S., Chen, S. H. & Kao, J., Jun 29 2012, In: PLoS ONE. 7, 6, e38465.

**Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases**

Tong, C. C. L., Ko, E. C., Sung, M. W., Cesaretti, J. A., Stock, R. G., Packer, S. H., Forsythe, K., Genden, E. M., Schwartz, M., Lau, K. H. V., Galsky, M., Ozao-Choy, J., Chen, S. H. & Kao, J., Jun 27 2012, In: PLoS ONE. 7, 6, e36979.

**Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release**

Jayaraman, P., Parikh, F., Lopez-Rivera, E., Hailemichael, Y., Clark, A., Ma, G., Cannan, D., Ramacher, M., Kato, M., Overwijk, W. W., Chen, S. H., Umansky, V. Y. & Sikora, A. G., Jun 1 2012, In: Journal of Immunology. 188, 11, p. 5365-5376 12 p.

**R-Ras is required for murine dendritic cell maturation and CD4<sup>+</sup> T-cell priming**

Singh, G., Hashimoto, D., Yan, X., Helft, J., Park, P. J. Y., Ma, G., Qiao, R. F., Kennedy, C. R., Chen, S. H., Merad, M. & Chan, A. M., Feb 16 2012, In: *Blood*. 119, 7, p. 1693-1701 9 p.

**Myeloid-derived suppressive cells and their regulatory mechanisms in cancer**

Ma, G., Pan, P-Y. & Chen, S-H., Jan 1 2012, *Innate Immune Regulation and Cancer Immunotherapy*. Springer New York, p. 231-250 20 p.

**Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development**

Zheng, J., Umikawa, M., Cui, C., Li, J., Chen, X., Zhang, C., Hyunh, H., Kang, X., Silvany, R., Wan, X., Ye, J., Cantó, A. P., Chen, S. H., Wang, H. Y., Ward, E. S. & Zhang, C. C., 2012, In: *Nature*. 485, 7400, p. 656-660 5 p.

**DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity**

Peng, S., Ma, B., Chen, S. H., Hung, C. F. & Wu, T. C., Jul 28 2011, In: *Cell and Bioscience*. 1, 1, 26.

**Erratum: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases (Cancer (2009) 115 (3571-80))**

Kao, J., Packer, S., Vu, H. L., Schwartz, M. E., Sung, M. W., Stock, R. G., Lo, Y. C., Huang, D., Chen, S. H. & Cesaretti, J. A., Jun 15 2011, In: *Cancer*. 117, 12, p. 2826 1 p.

**Paired immunoglobulin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells**

Ma, G., Pan, P. Y., Eisenstein, S., Divino, C. M., Lowell, C. A., Takai, T. & Chen, S. H., Mar 25 2011, In: *Immunity*. 34, 3, p. 385-395 11 p.

**A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer**

Meseck, M., Huang, T., Ma, G., Wang, G., Chen, S. H. & Woo, S. L. C., Mar 2011, In: *Journal of Immunotherapy*. 34, 2, p. 175-182 8 p.

**Targeting immune suppressing myeloid-derived suppressor cells in oncology**

Kao, J., Ko, E. C., Eisenstein, S., Sikora, A. G., Fu, S. & Chen, S. H., Jan 2011, In: *Critical Reviews in Oncology/Hematology*. 77, 1, p. 12-19 8 p.

**Myeloid-derived suppressor cells prevent type 1 diabetes in murine models**

Yin, B., Ma, G., Yen, C. Y., Zhou, Z., Wang, G. X., Divino, C. M., Casares, S., Chen, S. H., Yang, W. C. & Pan, P. Y., Nov 15 2010, In: *Journal of Immunology*. 185, 10, p. 5828-5834 7 p.

**Myeloid-derived suppressor cells: Natural regulators for transplant tolerance**

Boros, P., Ochando, J. C., Chen, S. H. & Bromberg, J. S., Nov 2010, In: *Human Immunology*. 71, 11, p. 1061-1066 6 p.

**Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice**

Garcia, M. R., Ledgerwood, L., Yang, Y., Xu, J., Lal, G., Burrell, B., Ma, G., Hashimoto, D., Li, Y., Boros, P., Grisotto, M., Van Rooijen, N., Matesanz, R., Tacke, F., Ginhoux, F., Ding, Y., Chen, S. H., Randolph, G., Merad, M., Bromberg, J. S., & 1 othersOchando, J. C., Jul 1 2010, In: *Journal of Clinical Investigation*. 120, 7, p. 2486-2496 11 p.

**Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells**

Zhou, Z., French, D. L., Ma, G., Eisenstein, S., Chen, Y., Divino, C. M., Keller, G., Chen, S. H. & Pan, P. Y., Mar 31 2010, In: *STEM CELLS*. 28, 3, p. 620-632 13 p.

**Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer**

Pan, P. Y., Ma, G., Weber, K. J., Ozao-Choy, J., Wang, G., Yin, B., Divino, C. M. & Chen, S. H., Jan 1 2010, In: *Cancer research*. 70, 1, p. 99-108 10 p.

**Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: Acute toxicity and preliminary response**

Kao, J., Packer, S., Ha, L. V., Schwartz, M. E., Sung, M. W., Stock, R. G., Lo, Y. C., Huang, D., Chen, S. H. & Cesaretti, J. A., Aug 1 2009, In: *Cancer*. 115, 15, p. 3571-3580 10 p.

**The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies**

Ozao-Choy, J., Ge, M., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P. Y. & Chen, S. H., Mar 15 2009, In: *Cancer research*. 69, 6, p. 2514-2522 9 p.

**Interleukin 10 suppresses Th17 cytokines secreted by macrophages and T cells**

Gu, Y., Yang, J., Ouyang, X., Liu, W., Li, H., Yang, J., Bromberg, J., Chen, S. H., Mayer, L., Unkeless, J. C. & Xiong, H., Jul 2008, In: *European Journal of Immunology*. 38, 7, p. 1807-1813 7 p.

**Advancements in immune tolerance**

Pan, P. Y., Ozao, J., Zhou, Z. & Chen, S. H., Jan 14 2008, In: *Advanced Drug Delivery Reviews*. 60, 2, p. 91-105 15 p.

**Reversion of immune tolerance in advanced malignancy: Modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function**

Pan, P. Y., Wang, G. X., Yin, B., Ozao, J., Ku, T., Divino, C. M. & Chen, S. H., Jan 1 2008, In: *Blood*. 111, 1, p. 219-228 10 p.

**The terminology issue for myeloid-derived suppressor cells [1]**

Gabrilovich, D. I., Bronte, V., Chen, S. H., Colombo, M. P., Ochoa, A., Ostrand-Rosenberg, S. & Schreiber, H., Jan 1 2007, In: *Cancer research*. 67, 1, p. 425 1 p.

**Gr-1<sup>+</sup>CD115<sup>+</sup> immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host**

Huang, B., Pan, P. Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M. & Chen, S. H., Jan 15 2006, In: *Cancer research*. 66, 2, p. 1123-1131 9 p.

**Erratum: Toll-like receptors on tumor cells facilitate evasion of immune surveillance (Cancer Research (June 15, 2005) 65 (5009-5014))**

Huang, B., Zhao, J., Li, H., He, K. L., Chen, Y., Chen, S. H., Mayer, L., Unkeless, J. C. & Xiong, H., Oct 1 2005, In: *Cancer research*. 65, 19, 1 p.

**The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma**

Xu, D. P., Sauter, B. V., Huang, T. G., Meseck, M., Woo, S. L. C. & Chen, S. H., Oct 2005, In: *Gene Therapy*. 12, 20, p. 1526-1533 8 p.

**NK and CD8<sup>+</sup> T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation**

Xu, D., Gu, P., Pan, P. Y., Li, Q., Sato, A. I. & Chen, S. H., Apr 20 2004, In: *International Journal of Cancer*. 109, 4, p. 499-506 8 p.

**Regulation of Dendritic Cell Function by NK Cells: Mechanisms Underlying the Synergism in the Combination Therapy of IL-12 and 4-1BB Activation**

Pan, P. Y., Gu, P., Li, Q., Xu, D., Weber, K. & Chen, S. H., Apr 15 2004, In: *Journal of Immunology*. 172, 8, p. 4779-4789 11 p.

**Role of Immature Myeloid Gr-1<sup>+</sup> Cells in the Development of Antitumor Immunity**

Li, Q., Pan, P. Y., Gu, P., Xu, D. & Chen, S. H., Feb 1 2004, In: *Cancer research*. 64, 3, p. 1130-1139 10 p.

**In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery**

Pan, P. Y., Li, Y., Li, Q., Gu, P., Martinet, O., Thung, S. & Chen, S. H., Jan 2004, In: *Cancer Immunology, Immunotherapy*. 53, 1, p. 17-25 9 p.

**IFN- $\gamma$  sensitization of prostate cancer cells to Fas-mediated death: A gene therapy approach**

Selleck, W. A., Canfield, S. E., Hassen, W. A., Meseck, M., Kuzmin, A. I., Eisensmith, R. C., Chen, S. H. & Hall, S. J., Feb 1 2003, In: *Molecular Therapy*. 7, 2, p. 185-192 8 p.

**OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases**

Pan, P. Y., Zang, Y., Weber, K., Meseck, M. L. & Chen, S. H., Oct 1 2002, In: *Molecular Therapy*. 6, 4, p. 528-536 9 p.

**An ATF2-derived peptide sensitizes melanomas to apoptosis and inhibits their growth and metastasis**

Bhoumik, A., Huang, T. G., Ivanov, V., Gangi, L., Qiao, R. F., Woo, S. L. C., Chen, S. H. & Ronai, ZEE., Sep 2002, In: *Journal of Clinical Investigation*. 110, 5, p. 643-650 8 p.

**A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer**

Hall, S. J., Canfield, S. E., Yan, Y., Hassen, W., Selleck, W. A. & Chen, S. H., 2002, In: *Gene Therapy*. 9, 8, p. 511-517 7 p.

**Intratumoral delivery of adenovirus-mediated interleukin-12 gene in mice with metastatic cancer in the liver**

Sung, M. W., Chen, S. H., Thung, S. N., Zhang, D. Y., Huang, T. G., Mandeli, J. P. & Woo, S. L. C., 2002, In: *Human Gene Therapy*. 13, 6, p. 731-743 13 p.

**T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer**

Martinet, O., Divino, C. M., Zang, Y., Gan, Y., Mandeli, J., Thung, S., Pan, P. Y. & Chen, S. H., 2002, In: *Gene Therapy*. 9, 12, p. 786-792 7 p.

**Tumor-specific transcriptional targeting of suicide gene therapy**

Qiao, J., Doubrovin, M., Sauter, B. V., Huang, Y., Guo, Z. S., Balatoni, J., Akhurst, T., Blasberg, R. G., Tjuvajev, J. G., Chen, S. H. & Woo, S. L. C., 2002, In: *Gene Therapy*. 9, 3, p. 168-175 8 p.

**Independent contributions of GR-1<sup>+</sup> leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer**

Sanford, M. A., Yan, Y., Canfield, S. E., Hassan, W., Selleck, W. A., Atkinson, G., Chen, S. H. & Hall, S. J., Aug 10 2001, In: *Human Gene Therapy*. 12, 12, p. 1485-1498 14 p.

**Methods for cancer gene therapy.**

Kwong, Y. L., Chen, S. H. & Woo, S. L., May 2001, In: *Current protocols in human genetics / editorial board, Jonathan L. Haines ... [et al.]*. Chapter 13, p. Unit 13.5

**Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial**

Sung, M. W., Yeh, H. C., Thung, S. N., Schwartz, M. E., Mandeli, J. P., Chen, S. H. & Woo, S. L. C., 2001, In: *Molecular Therapy*. 4, 3, p. 182-191 10 p.

**Gr-1<sup>+</sup> myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation**

Kusmartsev, S. A., Li, Y. & Chen, S. H., Jul 15 2000, In: *Journal of Immunology*. 165, 2, p. 779-785 7 p.

**Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation**

Chen, S. H., Pham-Nguyen, K. B., Martinet, O., Huang, Y., Yang, W., Thung, S. N., Chen, L., Mittler, R. & Woo, S. L. C., Jul 2000, In: *Molecular Therapy*. 2, 1, p. 39-46 8 p.

**A novel immunocytolytic factor secreted by pancreatic adenocarcinoma**

Angel, L. P., Divino, C. M., Brower, S. T. & Chen, S. H., Jun 15 2000, In: *Journal of Surgical Research.* 91, 2, p. 154-158 5 p.

**Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: Long-term remission of liver metastases in a mouse model**

Martinet, O., Ermekova, V., Qiao, J. Q., Sauter, B., Mandeli, J., Chen, L. & Chen, S. H., Jun 7 2000, In: *Journal of the National Cancer Institute.* 92, 11, p. 931-936 6 p.

**Phase I Study of Adenoviral Delivery of the HSV-tk Gene and Ganciclovir Administration in Patients with Recurrent Malignant Brain Tumors**

Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S. H., Woo, S. L. C. & Grossman, R. G., Feb 2000, In: *Molecular Therapy.* 1, 2, p. 195-203 9 p.

**Anti-tumor immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells**

Divino, C. M., Chen, S. H., Yang, W., Thung, S., Brower, S. T. & Woo, S. L. C., 2000, In: *Breast Cancer Research and Treatment.* 60, 2, p. 129-134 6 p.

**Gene therapy of metastatic colon carcinoma: Regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase**

Block, A., Freund, C. T. F., Chen, S-H., Nguyen, K. P., Finegold, M., Windler, E. & Woo, S. L. C., 2000, In: *Cancer Gene Therapy.* 7, 3, p. 438-445 8 p.

**Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer**

Hassan, W., Sanford, M. A., Woo, S. L. C., Chen, S. H. & Hall, S. J., 2000, In: *World Journal of Urology.* 18, 2, p. 130-135 6 p.

**Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo**

Tjuvajev, J. G., Chen, S. H., Joshi, A., Joshi, R., Guo, Z. S., Balatoni, J., Ballon, D., Koutcher, J., Finn, R., Woo, S. L. & Blasberg, R. G., Oct 15 1999, In: *Cancer research.* 59, 20, p. 5186-5193 8 p.

**Characterization of a novel immunocytolytic factor secreted by pancreatic adenocarcinoma**

Divino, C. M., Angel, L. P., Brower, S. T. & Chen, S. H., 1999, In: *Oncology Research.* 11, 11-12, p. 489-495 7 p.

**Construction and characterization of a recombinant adenoviral vector expressing human interleukin-12**

Qiao, J., Chen, S. H., Pham-Nguyen, K. B., Mandeli, J. & Woo, S. L. C., 1999, In: *Cancer Gene Therapy.* 6, 4, p. 373-379 7 p.

**Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma**

Pham-Nguyen, K. B., Yang, W., Saxena, R., Thung, S. N., Woo, S. L. C. & Chen, S. H., 1999, In: *International Journal of Cancer.* 81, 5, p. 813-819 7 p.

**Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer**

Hall, S. J., Sanford, M. A., Atkinson, G. & Chen, S-H., Aug 1 1998, In: *Cancer research.* 58, 15, p. 3221-3225 5 p.

**Adenovirus-mediated ex vivo immunogene and in vivo combination gene therapy strategies induce a systemic anti-tumor immune defense in the mouse B16 melanoma model**

Bonnekoh, B., Greenhalgh, D. A., Chen, S. H., Bickenbach, J., Block, A., Rich, S. S., Krieg, T., Woo, S. L. C. & Roop, D. R., 1998, In: *Advances in experimental medicine and biology.* 451, p. 335-343 9 p.

**Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat**

Rojas-Martinez, A., Wyde, P. R., Montgomery, C. A., Chen, S. H., Woo, S. L. C. & Aguilar-Cordova, E., 1998, In: *Cancer Gene Therapy*. 5, 6, p. 365-370 6 p.

**Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model**

Bonnekoh, B., Greenhalgh, D. A., Chen, S. H., Block, A., Rich, S. S., Krieg, T., Woo, S. L. C. & Roop, D. R., 1998, In: *Journal of Investigative Dermatology*. 110, 6, p. 867-871 5 p.

**The promise and reality of cancer gene therapy**

Hall, S. J., Chen, S. H. & Woo, S. L. C., Oct 1997, In: *American Journal of Human Genetics*. 61, 4, p. 785-789 5 p.

**Adenovirus-mediated suicide gene therapy for experimental bladder cancer**

Sutton, M. A., Berkman, S. A., Chen, S-H., Block, A., Dang, T. D., Kattan, M. W., Wheeler, T. M., Rowley, D. R., Woo, S. L. C. & Lerner, S. P., Feb 1997, In: *Urology*. 49, 2, p. 173-180 8 p.

**Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: Regression of hepatic metastasis of pancreatic tumors**

Block, A., Chen, S-H., Kosai, K. I., Finegold, M. & Woo, S. L. C., Jan 1 1997, In: *Pancreas*. 15, 1, p. 25-34 10 p.

**Combination therapy with suicide and cytokine genes for hepatic metastases of lung cancer**

Kwong, Y. L., Chen, S-H., Kosai, K., Finegold, M. & Woo, S. L. C., Jan 1 1997, In: *CHEST*. 112, 5, p. 1332-1337 6 p.

**Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer**

Hall, S. J., Mutchnik, S. E., Chen, S. H., Woo, S. L. C. & Thompson, T. C., 1997, In: *International Journal of Cancer*. 70, 2 , p. 183-187 5 p.

**Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat)**

Shine, H. D., Wyde, P. R., Aguilar-Cordova, E., Chen, S. H., Woo, S. L. C., Grossman, R. G. & Goodman, J. C., 1997, In: *Gene Therapy*. 4, 4, p. 275-279 5 p.

**The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer**

O'Malley, B. W., Sewell, D. A., Li, D., Kosai, K. I., Chen, S. H., Woo, S. L. C. & Duan, L., 1997, In: *Molecular Endocrinology*. 11, 6, p. 667-673 7 p.

**Gene therapy for hepatocellular carcinoma: Long-term remission of primary and metastatic tumors in mice by interleukin-2 gene therapy in vivo**

Huang, H., Chen, S. H., Kosai, K., Finegold, M. J. & Woo, S. L. C., Dec 9 1996, In: *Gene Therapy*. 3, 11, p. 980-987 8 p.

**Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma**

Caruso, M., Pham-Nguyen, K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L. C. & Chen, S. H., Oct 15 1996, In: *Proceedings of the National Academy of Sciences of the United States of America*. 93, 21, p. 11302-11306 5 p.

**Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival**

Chen, S. H., Kosai, K. I., Xu, B., Pham-Nguyen, K., Contant, C., Finegold, M. J. & Woo, S. L. C., Aug 15 1996, In: *Cancer research*. 56, 16, p. 3758-3762 5 p.

**Adenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir**

Tong, X. W., Block, A., Chen, S. H., Woo, S. L. C. & Kieback, D. G., Jul 1 1996, In: *Anticancer Research*. 16, 4 A, p. 1611-1617 7 p.

**Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: Pathologic, radiologic, and molecular studies**

Goodman, J. C., Trask, T. W., Chen, S. H., Woo, S. L. C., Grossman, R. G., Carey, K. D., Hubbard, G. B., Carrier, D. A., Rajagopalan, S., Aguilar-Cordova, E. & Shine, H. D., Jun 20 1996, In: Human Gene Therapy. 7, 10, p. 1241-1250 10 p.

**Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer**  
Yee, D., McGuire, S. E., Brünner, N., Kozelsky, T. W., Allred, D. C., Chen, S. H. & Woo, S. L. C., Jun 20 1996, In: Human Gene Therapy. 7, 10, p. 1251-1257 7 p.

**Combination gene therapy for oral cancer in a murine model**

O'Malley, B. W., Cope, K. A., Chen, S. H., Li, D., Schwartz, M. R. & Woo, S. L. C., Apr 15 1996, In: Cancer research. 56, 8 , p. 1737-1741 5 p.

**Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models**

Eastham, J. A., Chen, S. H., Sehgal, I., Yang, G., Timme, T. L., Hall, S. J., Woo, S. L. C. & Thompson, T. C., Mar 1 1996, In: Human Gene Therapy. 7, 4, p. 515-523 9 p.

**In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration**

Tong, X. W., Block, A., Chen, S. H., Contant, C. F., Agoulnik, I., Blankenburg, K., Kaufman, R. H., Woo, S. L. C. & Kieback, D. G., Jan 1 1996, In: Gynecologic oncology. 61, 2, p. 175-179 5 p.

**Adenoviral-mediated herpes simplex virus-thymidine kinase gene transfer in vivo for treatment of experimental human melanoma**

Bonnekoh, B., Greenhalgh, D. A., Bundman, D. S., Kosai, K. I., Chen, S. H., Finegold, M. J., Krieg, T., Woo, S. L. C. & Roop, D. R., 1996, In: Journal of Investigative Dermatology. 106, 6, p. 1163-1168 6 p.

**Adenovirus-mediated gene therapy in an experimental model of breast cancer metastatic to the brain**

Colak, A., Goodman, J. C., Chen, S. H., Woo, S. L. C., Grossman, R. G. & Shine, H. D., Oct 1995, In: Human Gene Therapy. 6, 10, p. 1317-1322 6 p.

**Adenovirus-mediated gene therapy for experimental spinal cord tumors: tumoricidal efficacy and functional outcome**

Çolak, A., Clay Goodman, J., Chen, S. H., Woo, S. L. C., Grossman, R. G. & David Shine, H., Sep 11 1995, In: Brain Research. 691, 1-2, p. 76-82 7 p.

**Deletion of integrated hepatitis B virus genome and cellular flanking sequences in hepatocellular carcinoma cells in BALB/c mice**

Chang, P. C., Hu, C. P., Chen, S. H., Wang-Wuu, S. & Chang, C., Jun 1995, In: Hepatology. 21, 6, p. 1504-1509 6 p.

**Combination gene therapy for liver metastasis of colon carcinoma in vivo**

Chen, S. H., Li Chen, X. H., Wang, Y., Kosai, K. I., Finegold, M. J., Rich, S. S. & Woo, S. L. C., Mar 28 1995, In: Proceedings of the National Academy of Sciences of the United States of America. 92, 7, p. 2577-2581 5 p.

**Adenovirus-mediated Gene Therapy for Human Head and Neck Squamous Cell Cancer in a Nude Mouse Model**

O'Malley, B. W., Chen, S. H., Schwartz, M. R. & Woo, S. L. C., Mar 1 1995, In: Cancer research. 55, 5, p. 1080-1085 6 p.

**Inhibition of melanoma growth by adenoviral-mediated HSV thymidine kinase gene transfer in vivo**

Bonnekoh, B., Greenhalgh, D. A., Bundman, D. S., Eckhardt, J. N., Longley, M. A., Chen, S. H., Woo, S. L. C. & Roop, D. R., 1995, In: Journal of Investigative Dermatology. 104, 3, p. 313-317 5 p.

**Adenovirus-mediated gene therapy of experimental gliomas**

Perez-Cruet, M. J., Trask, T. W., Chen, S. H., Goodman, J. C., Woo, S. L. C., Grossman, R. G. & Shine, H. D., Nov 1 1994, In: Journal of Neuroscience Research. 39, 4, p. 506-511 6 p.

**Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo**  
Chen, S. H., Shine, H. D., Goodman, J. C., Grossman, R. G. & Woo, S. L. C., Apr 12 1994, In: Proceedings of the National Academy of Sciences of the United States of America. 91, 8, p. 3054-3057 4 p.

**Immune Reactions against Hepatitis B Viral Antigens Lead to the Rejection of Hepatocellular Carcinoma in BALB/c Mice**  
Chen, S-H., Hu, C. P., Lee, C. K. & Chang, C., Oct 1 1993, In: Cancer research. 53, 19, p. 4648-4651 4 p.

**Hepatitis B Virus Replication in Well Differentiated Mouse Hepatocyte Cell Lines Immortalized by Plasmid DNA**  
Chen, S-H., Hu, C. P. & Chang, C., Jan 1 1992, In: Cancer research. 52, 5, p. 1329-1335 7 p.

## Activities

**National Science and Technology Council, Taiwan (External organization)**  
Shu-Hsia Chen (Reviewer)  
Dec 27 2023 → Dec 28 2023

**Faculty Appointment and Promotion Committee for Academic Sinica (External organization)**  
Shu-Hsia Chen (Member)  
Dec 6 2023

**International Cancer Immunotherapy Conference**  
Shu-Hsia Chen (Participant)  
Sep 20 2023 → Sep 23 2023

**Harnessing neutrophils to improve the efficacy of immune checkpoint inhibitors in breast cancer**  
Shu-Hsia Chen (Mentor)  
Jun 8 2023 → May 31 2025

**The structure-activity of macromolecular platinum-based compounds for colorectal and ovarian cancer.**  
Shu-Hsia Chen (Mentor)  
May 1 2023 → Apr 30 2025

**From Laboratory to the Clinic: Overcoming Immunotherapy Failure from Non-responders To Responders**  
Shu-Hsia Chen (Speaker)  
Apr 6 2023 → Apr 7 2023

**THE LANDSCAPE OF SOLID TUMOR-INDUCED SYSTEMIC IMMUNE ALTERATION AT SINGLE-CELL RESOLUTION**  
Shu-Hsia Chen (Mentor)  
Feb 23 2023

**Elucidating Response to Anti-TNF- $\alpha$  in Patients with Ulcerative Colitis Using Imaging Mass Cytometry**  
Shu-Hsia Chen (Mentor)  
Jan 1 2023

**National Science and Technology Council, Taiwan (External organization)**  
Shu-Hsia Chen (Member)  
Jan 1 2023 → ...

**"The Plasticity of Myeloid Cell Differentiation and Macrophage Function in Tumor Microenvironment"**  
Shu-Hsia Chen (Speaker)  
Nov 7 2022 → Nov 11 2022

**"Modulating Microglia in Alzheimer's Disease"**

Shu-Hsia Chen (Speaker)

Oct 26 2022

**"From Laboratory to the Clinic: Medicine After COVID"**

Shu-Hsia Chen (Speaker)

Oct 18 2022

**"Medicine After COVID"**

Shu-Hsia Chen (Speaker)

Sep 10 2022 → Sep 11 2022

**Advisor for Baylor PhD student Che-Hsing "Kevin" Li thesis committee member and Susan Komen grant**

Shu-Hsia Chen (Mentor)

Jul 1 2022 → ...

**Advisor for Baylor PhD student Hai Wang thesis committee member and Susan Komen grant**

Shu-Hsia Chen (Mentor)

Jul 1 2022 → ...

**Christopher Fan, MD, PhD mentor, clinical investigator award for Houston Methodist Academic Institute**

Shu-Hsia Chen (Mentor)

Jul 1 2022 → ...

**Mentor for Texas A&M MD, PhD student Rachel Dubuque, MD, PhD**

Shu-Hsia Chen (Mentor)

Jul 1 2022 → ...

**"Analyzing One Cell at a Time: Analysis of Myeloid Cell Contribution in the Inflammatory Microenvironment"**

Shu-Hsia Chen (Speaker)

Jun 29 2022

**Mentor for Texas A&M MD, PhD student Alan Hodge, MD, PhD**

Shu-Hsia Chen (Mentor)

Jul 1 2021 → ...

**Keystone Symposia: Virtual Keystone Symposia 2021**

Shu-Hsia Chen (Participant)

Mar 22 2021 → Mar 24 2021

**NCI (External organization)**

Shu-Hsia Chen (Reviewer)

Jan 1 2021 → ...

**Identification of Epigenetic and Immune Biomarker Changes During the Progression of Non-Alcohol Fatty Disease (NAFLD) - related Hepatocellular Carcinoma**

Shu-Hsia Chen (Invited speaker)

Nov 20 2020

**Plasticity of Myeloid derived Suppressor Cells in Immune Therapy**

Shu-Hsia Chen (Invited speaker)

Nov 10 2020

**LILRBs Clinical Implications**

Shu-Hsia Chen (Invited speaker)

Jul 1 2020

**Turning the Balance of Myeloid Cell Functions for Immune Therapies**  
Shu-Hsia Chen (Invited speaker)  
Feb 10 2020 → Feb 12 2020

**MRC Research and Innovation Foundation (External organization)**  
Shu-Hsia Chen (Reviewer)  
Jan 1 2020 → ...

**Mt. Sinai School of Medicine (External organization)**  
Shu-Hsia Chen (Reviewer)  
Jan 1 2020 → ...

**Turning the Balance of Myeloid Cell Functions for Immunotherapy**  
Shu-Hsia Chen (Speaker)  
Nov 19 2019 → Nov 20 2019

**Turning the balance of Inflammation for Cancer Immunotherapy**  
Shu-Hsia Chen (Speaker)  
Nov 1 2019

**Modulation of Innate Immunity to Control Human Disease**  
Shu-Hsia Chen (Speaker)  
Oct 27 2019 → Oct 28 2019

**Immune Modulation of the Tumor Microenvironment for Enhancing Cancer**  
Shu-Hsia Chen (Speaker)  
Oct 7 2019 → Oct 15 2019

**MDSC Mediated Immune Suppression for GVHD while Retaining Graft Versus Leukemia Activity**  
Shu-Hsia Chen (Speaker)  
Jul 17 2019 → Jul 30 2019

**Blocking Immunoinhibitory Receptor Reprograms Tumor-Associated Myeloid Cells and Promotes Antitumor Immunity**  
Shu-Hsia Chen (Speaker)  
Jun 7 2019 → Jun 12 2019

**M1: Innate Immune Receptors: Roles in Immunology and Beyond**  
Shu-Hsia Chen (Speaker)  
Mar 10 2019 → Mar 14 2019

**Blocking Immunoinhibitory Receptor Reprograms Tumor-Associated Myeloid Cells and Promotes Antitumor Immunity**  
Shu-Hsia Chen (Speaker)  
Mar 8 2019 → Mar 15 2019

**Blocking immunoinhibitory receptor reprograms tumor-associated myeloid cells and promotes antitumor immunity**  
Shu-Hsia Chen (Speaker)  
Nov 24 2018 → Dec 2 2018

**NCI (External organization)**  
Shu-Hsia Chen (Member)  
Sep 20 2018

**Imaging Mass Cytometry User Group Meeting**  
Shu-Hsia Chen (Participant)  
Sep 8 2018

**The role of innate immunity for a long term anti tumor memory**  
Shu-Hsia Chen (Invited speaker)  
Jun 30 2018

**Tumor Microenvironment and Immunotherapy Forum**  
Shu-Hsia Chen (Speaker)  
Jun 28 2018

**Keystone Symposia Neurodegenerative Disease & neuroinflammation Meetings**  
Shu-Hsia Chen (Participant)  
Jun 17 2018

**Turning balance of inflammation: Good or bad for cancer**  
Shu-Hsia Chen (Speaker)  
May 12 2018

**Turning balance of inflammation: Good or bad for cancer**  
Shu-Hsia Chen (Speaker)  
May 3 2018

**NCI (External organization)**  
Shu-Hsia Chen (Member)  
Mar 7 2018

**Novel Immune Checkpoint on Innate Immunity**  
Shu-Hsia Chen (Invited speaker)  
Jan 10 2018

**The Plasticity of myeloid cell differentiation and macrophage function in tumor microenvironment:**  
Shu-Hsia Chen (Invited speaker)  
Nov 21 2017

**Immunology Program at Houston Methodist**  
Shu-Hsia Chen (Invited speaker)  
Nov 3 2017

**Imaging Cytof (IMC) Workshop**  
Shu-Hsia Chen (Invited speaker)  
Sep 16 2017

**New class of checkpoint inhibitors**  
Shu-Hsia Chen (Keynote speaker)  
Aug 18 2017

**The Plasticity of myeloid cell differentiation and macrophage function in tumor microenvironment:**  
Shu-Hsia Chen (Invited speaker)  
Aug 10 2017

**The Plasticity of myeloid cell differentiation and macrophage function in tumor microenvironment**  
Shu-Hsia Chen (Invited speaker)  
Jun 18 2017

**The Plasticity of Myeloid Cell Differentiation and Macrophage Function in Tumor Microenvironment**  
Shu-Hsia Chen (Invited speaker)  
Feb 16 2017

**Tools and facilities (Current and future) Systematic Approach to a Translational Program**  
Shu-Hsia Chen (Keynote speaker)  
Jan 17 2017

**NIH (External organization)**  
Shu-Hsia Chen (Reviewer)  
Jan 1 2010 → ...

**DOD (CDMRP), Prostate Cancer Research Program (External organization)**  
Shu-Hsia Chen (Reviewer)  
Jan 1 2009 → ...

**DOD (CDMRP), Prostate Cancer Research Program (External organization)**  
Shu-Hsia Chen (Reviewer)  
2007

**National Center for Research Resources, NIH (External organization)**  
Shu-Hsia Chen (Ad hoc member)  
2005

**NIH, Center for Scientific Review, Special Emphasis Panel (External organization)**  
Shu-Hsia Chen (Ad hoc member)  
2005

**NIH, Center for Scientific Review, TTT study section (External organization)**  
Shu-Hsia Chen (Ad hoc member)  
2005

**NIH, Experimental Immunology study section (External organization)**  
Shu-Hsia Chen (Reviewer)  
2003

**NCI, RAID program (External organization)**  
Shu-Hsia Chen (Reviewer)  
2001

**NCI, RAID program (External organization)**  
Shu-Hsia Chen (Reviewer)  
1999

**American Association for Cancer Research (External organization)**  
Shu-Hsia Chen (Member)  
Jan 1 1995 → ...

**Society of Chinese Bioscientists in America (External organization)**  
Shu-Hsia Chen (Member)  
Jan 1 1995 → ...

**The American Association of Immunologists (External organization)**

Shu-Hsia Chen (Member)

Jan 1 1995 → ...

## **Prizes**

**"Engineered CAR-T cells for the treatment of diffuse large B cell lymphoma"**

Chen, Shu-Hsia (Recipient), Sep 18 2023

**Houston Methodist Presidential Award**

Chen, Shu-Hsia (Recipient), Nov 30 2023

## **Grants**

**IL-15 in Lupus**

Chen, S.

University of Houston: \$121,125.00

9/30/21 → 9/29/23